Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications.

Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T.

Oncol Lett. 2013 Jan;5(1):249-254. Epub 2012 Oct 10.

2.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

3.

KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.

Hao YX, Li YM, Ye M, Guo YY, Li QW, Peng XM, Wang Q, Zhang SF, Zhao HX, Zhang H, Li GH, Zhu JH, Xiao WH.

Oncol Lett. 2017 May;13(5):3608-3616. doi: 10.3892/ol.2017.5889. Epub 2017 Mar 22.

4.

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, François E, Saint-Paul MC, Pedeutour F.

Ann Surg Oncol. 2010 May;17(5):1429-34. doi: 10.1245/s10434-009-0864-z. Epub 2010 Jan 5.

PMID:
20049644
5.

Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.

Krol LC, 't Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE.

Eur J Cancer. 2012 May;48(7):1108-15. doi: 10.1016/j.ejca.2012.02.054. Epub 2012 Mar 23.

PMID:
22446020
6.

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.

Gattenlöhner S, Etschmann B, Kunzmann V, Thalheimer A, Hack M, Kleber G, Einsele H, Germer C, Müller-Hermelink HK.

J Oncol. 2009;2009:831626. doi: 10.1155/2009/831626. Epub 2010 Mar 10.

7.

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.

Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.

Oncol Rep. 2014 May;31(5):2115-22. doi: 10.3892/or.2014.3077. Epub 2014 Mar 11.

PMID:
24626880
8.

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.

Cejas P, López-Gómez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Díaz E, Burgos E, Gonzalez-Barón M, Feliu J.

Curr Cancer Drug Targets. 2012 Feb;12(2):124-31.

PMID:
22229245
9.

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.

Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE.

Clin Cancer Res. 2010 Feb 1;16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446. Epub 2010 Jan 26.

10.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

11.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

12.

KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.

Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, van der Spoel P, Ramírez-Moreno R, Verhoef C, Ijzermans JN, Wang Y, Gratama JW, Foekens JA, Sleijfer S, Martens JW.

Int J Cancer. 2013 Jul;133(1):130-41. doi: 10.1002/ijc.27987. Epub 2013 Feb 9.

13.

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.

Cejas P, López-Gómez M, Aguayo C, Madero R, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Larrauri J, López R, Casado E, Gonzalez-Barón M, Feliu J.

PLoS One. 2009 Dec 18;4(12):e8199. doi: 10.1371/journal.pone.0008199.

14.

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].

Robešová B, Bajerová M, Vašíková A, Ostřížková L, Hausnerová J, Kyclová J, Pospíšilová S, Mayer J, Dvořáková D.

Klin Onkol. 2013;26(1):25-30. Czech.

PMID:
23528169
15.

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.

Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K.

Dis Colon Rectum. 2011 Sep;54(9):1170-8. doi: 10.1097/DCR.0b013e31821d37a3.

PMID:
21825899
16.

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.

Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.

Cytopathology. 2011 Dec;22(6):358-64. doi: 10.1111/j.1365-2303.2010.00812.x. Epub 2010 Oct 4.

PMID:
21029218
17.
18.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
19.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.

PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.

20.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

Supplemental Content

Support Center